# VASO Corp: financial statements, quarterly

VASO · OTC · CIK 839087 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vaso.md) · [Financials](/companies/vaso/financials.md) · [Filings](/companies/vaso/filings.md) · [Insiders](/companies/vaso/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vaso/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [19.4](/filings/0001213900-24-098378.md) | [21.9 d](/filings/0001213900-25-026337.md) | [18.7](/filings/0001213900-25-044213.md) | [20.2](/filings/0001213900-25-076616.md) | [20.8](/filings/0001213900-25-110955.md) | [27.0 d](/filings/0001213900-26-037664.md) | [19.5](/filings/0001213900-26-057690.md) | [20.0](/filings/0001213900-25-076616.md) | [22.7](/filings/0001213900-25-110955.md) | [27.0 d](/filings/0001213900-26-037664.md) | [19.4](/filings/0001213900-26-057690.md) | [11.2](/filings/0001213900-26-090009.md) |
| Cost of revenue | $m | [7.4](/filings/0001213900-24-098378.md) | [7.9 d](/filings/0001213900-25-026337.md) | [7.8](/filings/0001213900-25-044213.md) | [8.1](/filings/0001213900-25-076616.md) | [9.0](/filings/0001213900-25-110955.md) | [9.8 d](/filings/0001213900-26-037664.md) | [8.1](/filings/0001213900-26-057690.md) | [2.4](/filings/0001213900-26-090009.md) | [8.8](/filings/0001213900-25-110955.md) | [9.4 d](/filings/0001213900-26-037664.md) | [7.8](/filings/0001213900-26-057690.md) | [2.3](/filings/0001213900-26-090009.md) |
| Gross profit | $m | [12.0](/filings/0001213900-24-098378.md) | [14.1 d](/filings/0001213900-25-026337.md) | [10.9](/filings/0001213900-25-044213.md) | [12.2](/filings/0001213900-25-076616.md) | [11.8](/filings/0001213900-25-110955.md) | [17.2 d](/filings/0001213900-26-037664.md) | [11.4](/filings/0001213900-26-057690.md) | [7.9](/filings/0001213900-26-090009.md) | [13.9](/filings/0001213900-25-110955.md) | [17.6 d](/filings/0001213900-26-037664.md) | [11.6](/filings/0001213900-26-057690.md) | [8.9](/filings/0001213900-26-090009.md) |
| Research and development | $m | [0.2](/filings/0001213900-24-098378.md) | [0.2 d](/filings/0001213900-25-026337.md) | [0.2](/filings/0001213900-25-044213.md) | [0.2](/filings/0001213900-25-076616.md) | [0.2](/filings/0001213900-25-110955.md) | [0.3 d](/filings/0001213900-26-037664.md) | [0.2](/filings/0001213900-26-057690.md) | [0.2](/filings/0001213900-26-090009.md) | [0.1](/filings/0001213900-25-110955.md) | [0.2 d](/filings/0001213900-26-037664.md) | [0.2](/filings/0001213900-26-057690.md) | [0.2](/filings/0001213900-26-090009.md) |
| Selling, general and administrative | $m | [10.9](/filings/0001213900-24-098378.md) | [12.4 d](/filings/0001213900-25-026337.md) | [12.1](/filings/0001213900-25-044213.md) | [10.8](/filings/0001213900-25-076616.md) | [11.4](/filings/0001213900-25-110955.md) | [14.7 d](/filings/0001213900-26-037664.md) | [12.4](/filings/0001213900-26-057690.md) | [7.7](/filings/0001213900-26-090009.md) | [12.2](/filings/0001213900-25-110955.md) | [15.5 d](/filings/0001213900-26-037664.md) | [12.7](/filings/0001213900-26-057690.md) | [7.7](/filings/0001213900-26-090009.md) |
| Operating income | $m | [0.9](/filings/0001213900-24-098378.md) | [1.0 d](/filings/0001213900-25-026337.md) | [(1.5)](/filings/0001213900-25-044213.md) | [1.0](/filings/0001213900-25-076616.md) | [(1.4)](/filings/0001213900-25-110955.md) | [2.2 d](/filings/0001213900-26-037664.md) | [(1.2)](/filings/0001213900-26-057690.md) | [0.1](/filings/0001213900-26-090009.md) | [1.5](/filings/0001213900-25-110955.md) | [(2.8) d](/filings/0001213900-26-037664.md) | [(1.3)](/filings/0001213900-26-057690.md) | [1.0](/filings/0001213900-26-090009.md) |
| Income tax | $m | [0.0](/filings/0001213900-24-098378.md) | [0.1 d](/filings/0001213900-25-026337.md) | [0.0](/filings/0001213900-25-044213.md) | [0.1](/filings/0001213900-25-076616.md) | [0.0](/filings/0001213900-25-110955.md) | [0.2 d](/filings/0001213900-26-037664.md) | [0.0](/filings/0001213900-26-057690.md) | [0.0](/filings/0001213900-26-090009.md) | [0.0](/filings/0001213900-25-110955.md) | [(3.0) d](/filings/0001213900-26-037664.md) | [(0.2)](/filings/0001213900-26-057690.md) | [0.4](/filings/0001213900-26-090009.md) |
| Net income | $m | [1.2](/filings/0001213900-24-098378.md) | [1.1 d](/filings/0001213900-25-026337.md) | [(1.2)](/filings/0001213900-25-110955.md) | [1.2](/filings/0001213900-25-110955.md) | [(1.2)](/filings/0001213900-25-110955.md) | [2.2 d](/filings/0001213900-26-037664.md) | [(1.1)](/filings/0001213900-26-090009.md) | [(0.2)](/filings/0001213900-26-090009.md) | [1.7](/filings/0001213900-25-110955.md) | [1.1 d](/filings/0001213900-26-037664.md) | [(0.9)](/filings/0001213900-26-090009.md) | [0.5](/filings/0001213900-26-090009.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001213900-24-098378.md) | not reported | [(0.01)](/filings/0001213900-25-044213.md) | [0.01](/filings/0001213900-25-076616.md) | [(0.01)](/filings/0001213900-25-110955.md) | not reported | [(0.01)](/filings/0001213900-26-057690.md) | [0.00](/filings/0001213900-26-090009.md) | [0.01](/filings/0001213900-25-110955.md) | not reported | [(0.01)](/filings/0001213900-26-057690.md) | [0.00](/filings/0001213900-26-090009.md) |
| Basic EPS | $ per share | [0.01](/filings/0001213900-24-098378.md) | not reported | [(0.01)](/filings/0001213900-25-044213.md) | [0.01](/filings/0001213900-25-076616.md) | [(0.01)](/filings/0001213900-25-110955.md) | not reported | [(0.01)](/filings/0001213900-26-057690.md) | [0.00](/filings/0001213900-26-090009.md) | [0.01](/filings/0001213900-25-110955.md) | not reported | [(0.01)](/filings/0001213900-26-057690.md) | [0.00](/filings/0001213900-26-090009.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [11.3](/filings/0001213900-25-026337.md) | [19.5](/filings/0001213900-24-043559.md) | [25.7](/filings/0001213900-24-068957.md) | [26.8](/filings/0001213900-24-098378.md) | [26.3](/filings/0001213900-26-037664.md) | [25.3](/filings/0001213900-25-044213.md) | [32.6](/filings/0001213900-25-076616.md) | [34.9](/filings/0001213900-25-110955.md) | [34.1](/filings/0001213900-26-090009.md) | not reported | [38.3](/filings/0001213900-26-090009.md) |
| Current assets | $m | [43.2](/filings/0001654954-23-014359.md) | [45.1](/filings/0001213900-25-026337.md) | [39.0](/filings/0001213900-24-043559.md) | [40.9](/filings/0001213900-24-068957.md) | [43.0](/filings/0001213900-24-098378.md) | [51.2](/filings/0001213900-26-037664.md) | [46.0](/filings/0001213900-25-044213.md) | [50.0](/filings/0001213900-25-076616.md) | [51.9](/filings/0001213900-25-110955.md) | [58.6](/filings/0001213900-26-090009.md) | [51.1](/filings/0001213900-26-057690.md) | [55.2](/filings/0001213900-26-090009.md) |
| Total assets | $m | [73.0](/filings/0001654954-23-014359.md) | [75.8](/filings/0001213900-25-026337.md) | [69.4](/filings/0001213900-24-043559.md) | [72.1](/filings/0001213900-24-068957.md) | [73.9](/filings/0001213900-24-098378.md) | [82.9](/filings/0001213900-26-037664.md) | [77.9](/filings/0001213900-25-044213.md) | [82.6](/filings/0001213900-25-076616.md) | [84.5](/filings/0001213900-25-110955.md) | [88.3](/filings/0001213900-26-090009.md) | [83.0](/filings/0001213900-26-057690.md) | [85.9](/filings/0001213900-26-090009.md) |
| Current liabilities | $m | [30.3](/filings/0001654954-23-014359.md) | [30.0](/filings/0001213900-25-026337.md) | [27.3](/filings/0001213900-24-043559.md) | [26.8](/filings/0001213900-24-068957.md) | [30.2](/filings/0001213900-24-098378.md) | [34.7](/filings/0001213900-26-037664.md) | [30.2](/filings/0001213900-25-044213.md) | [33.0](/filings/0001213900-25-076616.md) | [31.6](/filings/0001213900-25-110955.md) | [36.8](/filings/0001213900-26-090009.md) | [30.6](/filings/0001213900-26-057690.md) | [32.9](/filings/0001213900-26-090009.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [25.6](/filings/0001213900-24-098378.md) | [26.8](/filings/0001213900-26-037664.md) | [25.6](/filings/0001213900-25-110955.md) | [26.7](/filings/0001213900-25-110955.md) | [25.7](/filings/0001213900-25-110955.md) | [27.7](/filings/0001213900-26-090009.md) | [26.7](/filings/0001213900-26-090009.md) | [26.5](/filings/0001213900-26-090009.md) | [28.2](/filings/0001213900-25-110955.md) | [29.4](/filings/0001213900-26-090009.md) | [28.6](/filings/0001213900-26-090009.md) | [29.2](/filings/0001213900-26-090009.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.8 d](/filings/0001213900-24-098378.md) | [(1.6) d](/filings/0001213900-25-026337.md) | [(1.1)](/filings/0001213900-25-044213.md) | [2.8 d](/filings/0001213900-25-076616.md) | [1.9 d](/filings/0001213900-25-110955.md) | [(0.4) d](/filings/0001213900-26-037664.md) | [(0.6)](/filings/0001213900-26-057690.md) | [6.8 d](/filings/0001213900-26-090009.md) | [2.8 d](/filings/0001213900-25-110955.md) | [0.3 d](/filings/0001213900-26-037664.md) | [(12.6)](/filings/0001213900-26-057690.md) | [17.4 d](/filings/0001213900-26-090009.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.4](/filings/0001213900-26-057690.md) | [0.5 d](/filings/0001213900-26-090009.md) | not reported | not reported | [0.5](/filings/0001213900-26-057690.md) | [0.5 d](/filings/0001213900-26-090009.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [175](/filings/0001654954-23-014359.md) | [175](/filings/0001213900-24-043559.md) | [175](/filings/0001213900-24-068957.md) | [176](/filings/0001213900-24-098378.md) | [175](/filings/0001213900-25-044213.md) | [176](/filings/0001213900-25-076616.md) | [175](/filings/0001213900-25-110955.md) | [0.2](/filings/0001213900-26-057690.md) | [176](/filings/0001213900-26-090009.md) | [176](/filings/0001213900-25-110955.md) | [0.2](/filings/0001213900-26-057690.md) | [176](/filings/0001213900-26-090009.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 176,018,035 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090009.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.